Literature DB >> 12925043

Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study.

J Ahmadi1, K Ahmadi, J Ohaeri.   

Abstract

AIMS: To test the effect of a 50-mg day-1 dose of naltrexone in the maintenance treatment of intravenous-buprenorphine dependence in comparison with a 50-mg day-1 dose of methadone and also a 5-mg day-1 dose of buprenorphine over a 24-week treatment period. PARTICIPANTS: Two hundred and four intravenous-buprenorphine-dependent patients who met the DSM-IV criteria for opioid dependence were randomized to three equal groups and were treated in a clinic in Iran where they were also offered a weekly 0.5-h counselling session, in 2002.
FINDINGS: The mean age was 31.2 years (range 17-53). The majority [63.2%] was between 20 and 34 years of age. The educational level of most of them [55.4%] was between 6 and 12 years of study. Completion rates by groups were 83.8% for the 50-mg dose methadone group, 58.8% for the 5-mg dose buprenorphine group and 20.6% for the 50-mg dose naltrexone group (P = 0.000). Retention in the 50-mg methadone group was significantly better than in the 5-mg dose buprenorphine group (P = 0.001) and the 50-mg dose naltrexone group (P = 0.000). Retention in the 5-mg buprenorphine group was significantly better than in the 50-mg naltrexone dose group (P = 0.000).
CONCLUSIONS: Evaluation of the Iranian experience on this subject may be useful for other countries.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925043     DOI: 10.1046/j.1365-2362.2003.01218.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

Review 1.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

Review 2.  Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.

Authors:  Jonathan Feelemyer; Don Des Jarlais; Kamyar Arasteh; Abu S Abdul-Quader; Holly Hagan
Journal:  Addiction       Date:  2013-08-15       Impact factor: 6.526

Review 3.  Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

Authors:  Suzanne Nielsen; Wai Chung Tse; Briony Larance
Journal:  Cochrane Database Syst Rev       Date:  2022-09-05

4.  Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.

Authors:  R Douglas Bruce; Sumathi Govindasamy; Laurie Sylla; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

5.  Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.

Authors:  David Otiashvili; Gvantsa Piralishvili; Zura Sikharulidze; George Kamkamidze; Sabrina Poole; George E Woody
Journal:  Drug Alcohol Depend       Date:  2013-07-31       Impact factor: 4.492

6.  Management of relapse in naltrexone maintenance for heroin dependence.

Authors:  Maria A Sullivan; Fatima Garawi; Adam Bisaga; Sandra D Comer; Kenneth Carpenter; Wilfrid N Raby; Stephen J Anen; Adam C Brooks; Huiping Jiang; Evaristo Akerele; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2007-08-02       Impact factor: 4.492

Review 7.  The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV.

Authors:  Corrilynn O Hileman; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.495

8.  Single high-dose buprenorphine for opioid craving during withdrawal.

Authors:  Jamshid Ahmadi; Mina Sefidfard Jahromi; Dara Ghahremani; Edythe D London
Journal:  Trials       Date:  2018-12-10       Impact factor: 2.279

9.  Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.

Authors:  Jihoon Lim; Imen Farhat; Antonios Douros; Dimitra Panagiotoglou
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

10.  Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study.

Authors:  Jamshid Ahmadi; Ebrahim Moghimi Sarani; Mina Sefidfard Jahromi
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2019-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.